Interestingly, ErbB4 is for instance associated with the acquired resistance to ErbB2-inhibitors in HER2+ breast tumors, probably via a shift in the dependency towards ErbB4 signaling following continuous ErbB2 blocking, though additional resistance mechanisms should account (72). This evidence concerns the gene ERBB2 and breast neoplasm.